Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 0.64 |
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.64 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.49 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.49 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.49 |
| ▸ | SCN1A known ✓ | P35498 | 3/20 | 0.49 |
| ▸ | SCN2A known ✓ | Q99250 | 3/20 | 0.49 |
| ▸ | SCN3A known ✓ | Q9NY46 | 3/20 | 0.49 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.47 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.47 |
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.47 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.47 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.47 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301966 | 0.98 | HTR2A (0.67) | HTR2AHRH1LMNAPMP22TDP1 | |
| SCHEMBL7326678 | 0.98 | HTR2A (0.67) | HTR2AHRH1LMNAPMP22TDP1 | |
| Hydrochloric Acid SCHEMBL1123516 | 0.85 | HTR2A (0.58) | HTR2AHRH1LMNAPMP22TDP1 | |
| Methacrylic Acid SCHEMBL202040 | 0.84 | HTR2A (0.50) | HTR2AHRH1LMNAKDM4ESLC6A4 | |
| Acrylic Acid SCHEMBL28956302 | 0.84 | HTR2A (0.50) | HTR2AHRH1LMNAPMP22KDM4E | |
| Hydrochloric Acid SCHEMBL11383046 | 0.81 | HRH1 (0.95) | HTR2AHRH1LMNAPMP22TDP1 | |
| Hydrochloric Acid SCHEMBL5300345 | 0.80 | CARM1 (0.51) | HTR2AHRH1LMNASMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL27285239 | 0.79 | TDP1 (0.65) | HTR2AHRH1LMNAPMP22TDP1 | |
| SCHEMBL1802493 | 0.79 | HRH1 (1.00) | HTR2AHRH1LMNAPMP22TDP1 | |
| SCHEMBL9195200 | 0.78 | TAAR1 (0.47) | HTR2AHRH1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604906-B2 | Process for the preparation of 3-aryloxy-3-phenylpropylamine and salt thereof | ZCL CHEMICALS LIMITED (IN) | 2017-03-28 | — | — | US | disclosed |
| US-20160107983-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3-PHENYLPROPYLAMINE AND SALT THEREOF | COHANCE LIFESCIENCES LIMITED (IN) | 2016-04-21 | — | — | US | disclosed |
| WO-2015001565-A2 | \"AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3- PHENYLPROPYLAMINE AND SALT THEREOF\ | ZCL CHEMICALS LIMITED (IN) | 2015-01-08 | — | — | WO | disclosed |
| WO-2009141833-A2 | AN IMPROVED PROCESS FOR SYNTHESIZING HIGHLY PURE ATOMOXETINE | IND-SWIFT LABORATORIES LIMITED (IN) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008062473-A1 | PROCESS FOR PREPARING ATOMOXETINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008026227-A2 | A PROCESS FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE | MATRIX LABORATORIES LTD (IN) | 2008-03-06 | — | — | WO | disclosed |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | CONJUCHEM, INC. (CA) | 2004-08-12 | — | — | US | disclosed |
| US-6706892-B1 | ADMINSTERING MALEIMIDE DERIVATIVE TO COVALENTLY BOND PROTEIN; WOUND HEALING, ANTIBIOTIC, ANTIINFLAMMATORY, ANTICARCINOGENIC, HYPOTENSIVE, AND ANALGESIC AGENTS | CONJUCHEM, INC. (CA) | 2004-03-16 | — | — | US | disclosed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |
| EP-0336753-B1 | IMPROVEMENTS IN OR RELATING TO PROPANAMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1992-07-08 | — | — | EP | disclosed |
| CN-1036562-A | To propanamine derivatives or improve one's methods relevant with propanamine derivatives | LILLY CO ELI (US) | 1989-10-25 | — | — | CN | disclosed |
| EP-0336753-A1 | Improvements in or relating to propanamine derivatives | ELI LILLY AND COMPANY (US) | 1989-10-11 | — | — | EP | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4584404-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0031910-B1 | ANILINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESSES FOR THEIR PRODUCTION | MERCK PATENT GmbH (DE) | 1983-04-13 | — | — | EP | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| EP-0031910-A1 | Aniline derivatives, pharmaceutical preparations containing them and processes for their production | MERCK PATENT GmbH (DE) | 1981-07-15 | — | — | EP | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107983-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3-PHENYLPROPYLAMINE AND SALT THEREOF | PAH, TYR, NAT1 | HTR2A 442/4885HRH1 630/4885SLC6A4 162/4885 |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | OGFR, HDGF, SERPINA6 | HTR2A 751/4885HRH1 161/4885SLC6A4 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.